Eccrine Porocarcinoma: Clinical and Histopathological Study of 14 Patients with Special Emphasis on Sentinel Lymph Node Biopsy


  • Anna-Stiina Meriläinen Department of Surgery, The Central Hospital of Tavastia Proper, Hämeenlinna and University of Helsinki, Finland
  • Maria von Willenbrand-Bäckmann Department of Pathology Helsinki University Hospital and University of Helsinki, Finland
  • Harri Sihto Department of Pathology Helsinki University Hospital and University of Helsinki, Finland
  • Virve Koljonen Department of Plastic Surgery Helsinki University Hospital and University of Helsinki, Finland



eccrine porocarcinoma, sentinel lymph node biopsy, case series


Eccrine porocarcinoma is a rare skin adnexal tumour that affects elderly people. Most eccrine porocarcinomas are stage I or II according to the American Joint Committee on Cancer. The prognosis is good in early stages, but worsens when advanced. Since information on the use of sentinel lymph node biopsy in these patients is scarce, this study examined the records of all patients with eccrine porocarcinoma treated at Helsinki University Hospital during a 17-year period and focused on sentinel lymph node biopsy patients. The study identified 14 patients (9 male, 5 female). There were 2 metastases to the lymph nodes and 2 recurrences at initial referral to our institution. All primary tumours had wide local excision and 6 patients also had sentinel lymph node biopsy, of whom none had positive lymph nodes. There were no new metastases or recurrences during follow-up. Three patients died of causes other than eccrine porocarcinoma. When comparing the wide local excision only and wide local excision with sentinel lymph node biopsy groups, no parameters reached statistical significance. The decision process of the multidisciplinary tumour board meeting on whether to perform sentinel lymph node biopsy was not clear, perhaps due to the limited knowledge of eccrine porocarcinoma. Further studies and international collaboration are warranted.


Download data is not yet available.


Coburn JG, Smith JL. Hidroacanthoma simplex; an assessment of a selected group of intraepidermal basal cell epitheliomata and of their malignant homologues. Br J Dermatol 1956; 68: 400-418. DOI:

Pinkus H, Mehregan AH. Epidermotropic eccrine carcinoma. a case combining features of eccrine poroma and Paget's dermatosis. Arch Dermatol 1963; 88: 597-606. DOI:

Mishima Y, Morioka S. Oncogenic differentiation of the intraepidermal eccrine sweat duct: eccrine poroma, poroepithelioma and porocarcinoma. Dermatologica 1969; 138: 238-250. DOI:

Stam H, Lohuis PJFM, Zupan-Kajcovski B, Wouters MWJM, Van Der Hage JA, Visser O. Increasing incidence and survival of a rare skin cancer in the Netherlands. A population-based study of 2,220 cases of skin adnexal carcinoma. J Surg Oncol 2013; 107: 822-827. DOI:

Meriläinen AS, Pukkala E, Böhling T, Koljonen V. Malignant eccrine porocarcinoma in Finland during 2007 to 2017. Acta Derm Venereol 2021; 101: adv00363. DOI:

Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg 2018; 44: 1247-1261. DOI:

Behbahani S, Malerba S, Karanfilian KM, Warren CJ, Alhatem A, Samie FH. Demographics and outcomes of eccrine porocarcinoma: results from the National Cancer Database. Br J Dermatol 2020; 183: 161-163. DOI:

Goyal A, Marghitu T, Goyal N, Rubin N, Patel K, Goyal K, et al. Surgical management and lymph-node biopsy of rare malignant cutaneous adnexal carcinomas: a population-based analysis of 7591 patients. Arch Dermatol Res 2021; 313: 623-632. DOI:

Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 2001; 25: 710-720. DOI:

Shaw M, McKee PH, Lowe D, Black MM. Malignant eccrine poroma: a study of twenty-seven cases. Br J Dermatol 1982; 107: 675-680. DOI:

Salih AM, Kakamad FH, Essa RA, Rauf GM, Masrur SA, Shvan HM, et al. Porocarcinoma: a systematic review of literature with a single case report. Int J Surg Case Rep 2017; 30: 13-16. DOI:

Sawaya JL, Khachemoune A. Poroma: a review of eccrine, apocrine, and malignant forms. Int J Dermatol 2014; 53: 1053-1061. DOI:

Shiohara J, Koga H, Uhara H, Takata M, Saida T. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. J Dermatol 2007; 34: 516-522. DOI:

Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot-Barry M, Taieb A, et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol 2011; 165: 985-989. DOI:

Riera-Leal L, Guevara-Gutierrez E, Barrientos-Garcia JG, Madrigal-Kasem R, Briseno-Rodriguez G, Tlacuilo-Parra A. Eccrine porocarcinoma: epidemiologic and histopathologic characteristics. Int J Dermatol 2015; 54: 580-586. DOI:

Tsunoda K, Onishi M, Maeda F, Akasaka T, Sugai T, Amano H. Evaluation of sentinel lymph node biopsy for eccrine porocarcinoma. Acta Derm Venereol 2019; 99: 691-692. DOI:

Gómez-Zubiaur A, Medina-Montalvo S, Vélez-Velázquez MD, Polo-Rodríguez I. Eccrine porocarcinoma: patient characteristics, clinical and histopathologic features, and treatment in 7 cases. Actas Dermosifiliogr 2017; 108: e27-e32. DOI:

Prieto-Granada C, Castner N, Chen A, Li J, Yue B, Wong JY, et al. Behavior of cutaneous adnexal malignancies: a single institution experience. Pathol Oncol Res 2020; 26: 239-244. DOI:

Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg (Lond) 2017; 20: 74-79. DOI:

Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol 2013; 108: 57-62. DOI:

AJCC Cancer staging manual 6th and 7th edition: Springer; 2002 and 2010.

Kim HJ, Kim A, Moon KC, Seo SH, Kim IH, Kim A, et al. Eccrine porocarcinoma: a multicenter retrospective study with review of the literatures reported in Korea. Ann Dermatol 2020; 32: 223-229. DOI:

Ragi SD, Moseley I, Ouellette S, Rao B. Epidemiology and survival of eccrine porocarcinoma by sex in the united states: a surveillance, epidemiology, and end results database analysis. Dermatol Surg 2023; 49: 97-99. DOI:

Aniţei GM, Ioanid N, Bandol G, Gafton ER, Patraşcu AM, Ferariu D, et al. Porocarcinoma: a rare cause of lateral cervical tumor. Arch Clin Cases 2019; 6: 53-58. DOI:

Lee KA, Cioni M, Robson A, Bataille V. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab. BMJ Case Rep 2019; 12: e228917. DOI:

Reina S, Palombo D, Boscaneanu A, Solari N, Bertoglio S, Valle L, et al. Sentinel lymph node biopsy in porocarcinoma: a case report. Int J Surg Case Rep 2018; 53: 196-199. DOI:

Storino A, Drews RE, Tawa NE, Jr. Malignant cutaneous adnexal tumors and role of SLNB. J Am Coll Surg 2021; 232: 889-898. DOI:

Sahn RE, Lang PG. Sentinel lymph node biopsy for high-risk nonmelanoma skin cancers. Dermatol Surg 2007; 33: 786-792; discussion 792-783. DOI:



How to Cite

Meriläinen, A.-S., von Willenbrand-Bäckmann, M., Sihto, H., & Koljonen, V. (2023). Eccrine Porocarcinoma: Clinical and Histopathological Study of 14 Patients with Special Emphasis on Sentinel Lymph Node Biopsy. Acta Dermato-Venereologica, 103, adv11649.





Funding data